What smart money is saying about Liquidia Corporation
2 funds in our archive have pitched Liquidia Corporation — most recently Laughing Water Capital in December 2025.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Fund coverage · 2 theses
- Laughing Water CapitalDecember 2025
Liquidia Corporation has an approved, better-tolerated PAH/PH-ILD therapy gaining share with patent outcomes skewed favorably, creating substantial upside with manageable downside.
Read the full thesis - Arquitos Capital ManagementDecember 2025
Liquidia is a pulmonary hypertension drug company with a superior PRINT-based inhaled treprostinil launch, rapid market share gains, strong early cash flow, large pipeline opportunities, and potential upside from legal resolution and M&A.
Read the full thesis
Read every full thesis on Liquidia Corporation
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→